Exploring natural compounds to understand and influence membrane receptors
Synthesis and Evaluation of Alkaloids to Probe Membrane Receptors
This study is all about finding new natural compounds that can help us understand and improve how certain important receptors in our body work, which could lead to better treatments for different health issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10896366 on NIH RePORTER |
What this research studies
This research focuses on discovering new small molecules derived from natural products that can affect the function of important membrane receptors in the body, specifically G-protein coupled receptors (GPCRs) and ligand-gated ion channels (LGICs). The team at the University of Illinois at Chicago is developing efficient methods to synthesize these complex natural compounds and create libraries of their derivatives. By using advanced receptor assays, they aim to transform these natural products into powerful tools for studying how these receptors work, which could lead to new treatments for various health conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that involve G-protein coupled receptors or ligand-gated ion channels, such as neurological disorders or addiction.
Not a fit: Patients with conditions unrelated to membrane receptor function may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new medications that target specific receptors, improving treatment options for patients with conditions related to these receptors.
How similar studies have performed: Previous research has shown success in using natural products to develop new drugs targeting membrane receptors, indicating a promising approach.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Riley, Andrew — University of Illinois at Chicago
- Study coordinator: Riley, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.